Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A study to find evidence of real-world effectiveness of ocrelizumab compared with other disease-modifying therapies in multiple sclerosis patients

Next Previous
Search
Trial Profile

A study to find evidence of real-world effectiveness of ocrelizumab compared with other disease-modifying therapies in multiple sclerosis patients

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 20 May 2020

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ocrelizumab (Primary) ; Dimethyl fumarate; Fingolimod; Glatiramer acetate; Interferon beta-1a; Interferon beta-1b; Natalizumab; Peginterferon beta-1a; Teriflunomide
  • Indications Multiple sclerosis
  • Focus Therapeutic Use

    • Most Recent Events

    • 20 May 2020 New trial record
    • 01 May 2020 Preliminary results (n=2713) presented at the 72nd Annual Meeting of the American Academy of Neurology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top